). 228 Compounds were prepared in a 0.2-ml volume. The treatments 229 were administered to the mice for five consecutive days, beginning 230 6 h before viral inoculation, by oral gavage, using doses of 20, 30, 231 and 60 mg/kg of body weight/day of umifenovir, which was 232 administered once daily (in the morning), or doses of 2,5 and 233 10 mg/kg Q8 of body weight/day of oseltamivir, which was given 234 twice daily. The placebo was administered in parallel with the 235 antiviral treatments. Survival and weight changes were observed 236 for 21 days after virus inoculation. Animals that showed signs of 237 severe disease and weight loss of 25% were humanely euthanized. 238 The mice were weighed on days 0, 1, 2, 3, 4, 5, 7, 9, 11, 13, and 239 15 after infection, and the weight loss or gain was calculated for 240 each mouse as a percentage of its weight on day 0 before virus 241 inoculation. Oseltamivir treatments at 2.5 mg/kg/day protected 40% of the 360 infected animals, prevented weight loss (Figure 1 ), and resulted in 361 a mean survival time of 13.9 days compared with 7.5 days in the 362 untreated control mice. The most profound therapeutic effect was 363 observed for oseltamivir at 10 mg/kg/day. Oseltamivir administra-364 tion (10 mg/kg/day) completely protected the infected mice from 365 death and prevented weight loss (Figure 1 ). 
371
All specimens tested contained the S31N mutation in the M2 372 protein, which confers cross-resistance to the adamantane class of 373 anti-influenza drugs. 25 Mutations that led to an amino acid 374 substitution at H275Y in the NA protein, which cause resistance of 375 the A(H1N1)pdm09 influenza virus to oseltamivir, were found in 376 three of the 108 samples (2.8% of patients). No mutations that led 377 to amino acid substitutions in the HA2 protein, which cause 378 resistance of the influenza A virus to umifenovir, 11 were found in 379 the 108 samples tested. 1980-1990. 8,9 The present study is the 527 first to compare the clinical effectiveness of oseltamivir and 528 umifenovir. It was demonstrated that the effectiveness of umife-529 novir treatment is comparable to that of the standard anti-influenza 530 oseltamivir treatment and this is a welcome addition to the previous 531 clinical trial data regarding umifenovir effectiveness for the 532 treatment of influenza A and B infections. These data are 533 encouraging for the current ongoing double-blind, randomized, 534 placebo-controlled clinical trial for umifenovir that was initiated in 535 2012. The aim of that trial is to evaluate the efficacy and safety of 536 umifenovir for the treatment and prophylaxis of influenza and other 537 ARVIs. 33 
538
Recent meta-analysis studies have shown that there is no 539 evidence that oseltamivir reduces the likelihood of complications, 540 particularly hospitalization, pneumonia, or the combined outcome 541 of pneumonia and mortality, in an intention-to-treat (ITT) 542 population. [34] [35] [36] However, these studies have some limitations. 543 These works excluded many observational studies that found 544 oseltamivir to be helpful in normal clinical settings. 37 The evidence 545 from randomized clinical trials (RCTs) was further limited by the 546 lack of high-quality evidence for patient-important outcomes 547 under the treatment of specific subgroups, including hospitalized 548 and immune-compromised patients. Data obtained from RCTs 549 among high-risk patients were limited by the actual small number 550 of these patients. 36 Observational studies may provide more 551 information in addition to data currently available from RCTs for 552 certain elements of antiviral treatment. This benefit was reported 553 in detail in a recent review. 37 To supplement the information from 554 RCTs, the authors conducted a systematic review of observational 555 studies of antiviral treatment for influenza. These observational 556 studies suggested that oseltamivir may reduce mortality, hospi-557 talization, and symptom duration. Evidence from some observa-558 tional studies has also suggested that oral oseltamivir treatment 559 results in fewer complications, such as pneumonia, otitis media, 560 and any recurrent cardiovascular outcome. 564 There are some mismatches between the results of the meta-565 analysis studies with the highest level of evidence and the results 566 of observational studies, such as the level of evidence, which is not 567 notably high, but the conditions are close to those of real clinical 568 situations. This condition does not allow definitive conclusions to 569 be drawn about the benefit of antiviral treatments in individuals 570 and on influenza outcomes. Further high-quality RCT evidence is 571 needed to address important patient outcomes (e.g., mortality and 572 complications) and include hospitalized influenza patients. The 573 extrapolation of the results of such studies to the real clinical 574 situation is limited. Thus, observational studies are important and 575 additional tools that should be taken into consideration when 576 estimating the effectiveness of antiviral therapy. 577 Overall, the observational study results regarding the effective-578 ness of oseltamivir and umifenovir during the 2010-2011 579 influenza season are concordant with the experimental data 580 regarding the high susceptibility of influenza viruses that 581 circulated during this period to these antivirals. The sequence 582 analysis did not reveal mutations that are associated with 583 resistance to umifenovir, but the H275Y NA mutation responsible 584 for resistance to oseltamivir was found (3/108, 2%). As it is not 585 possible to conduct placebo-controlled clinical trials for antiviral 586 effectiveness in influenza-infected patients every season, such 587 studies may be used to inform clinical and public health practices. 
